Editas Medicine (EDIT) Competitors $2.47 -0.10 (-3.89%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$2.50 +0.03 (+1.17%) As of 09/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT vs. BEAM, CRSP, NTLA, CRON, ORIC, UPB, PHAR, TRVI, URGN, and PHATShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Cronos Group (CRON), Oric Pharmaceuticals (ORIC), Upstream Bio (UPB), Pharming Group (PHAR), Trevi Therapeutics (TRVI), Urogen Pharma (URGN), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Intellia Therapeutics Cronos Group Oric Pharmaceuticals Upstream Bio Pharming Group Trevi Therapeutics Urogen Pharma Phathom Pharmaceuticals Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do institutionals & insiders hold more shares of EDIT or BEAM? 71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 1.9% of Editas Medicine shares are owned by insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, EDIT or BEAM? Editas Medicine has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$32.31M6.87-$237.09M-$2.85-0.87Beam Therapeutics$63.52M25.97-$376.74M-$4.50-3.62 Is EDIT or BEAM more profitable? Editas Medicine has a net margin of -608.88% compared to Beam Therapeutics' net margin of -661.31%. Beam Therapeutics' return on equity of -43.15% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-608.88% -200.25% -68.57% Beam Therapeutics -661.31%-43.15%-31.06% Do analysts prefer EDIT or BEAM? Editas Medicine presently has a consensus price target of $5.10, suggesting a potential upside of 106.48%. Beam Therapeutics has a consensus price target of $48.45, suggesting a potential upside of 197.08%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 2 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.23Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.07 Which has more volatility and risk, EDIT or BEAM? Editas Medicine has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Does the media prefer EDIT or BEAM? In the previous week, Editas Medicine had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for Editas Medicine and 6 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 1.64 beat Editas Medicine's score of 0.64 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryBeam Therapeutics beats Editas Medicine on 11 of the 17 factors compared between the two stocks. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$231.10M$3.12B$5.75B$9.77BDividend YieldN/A2.28%6.66%4.50%P/E Ratio-0.8720.8682.5826.39Price / Sales6.87396.75535.42110.55Price / CashN/A43.5325.7028.92Price / Book11.768.1011.196.58Net Income-$237.09M-$53.35M$3.28B$265.84M7 Day Performance-7.49%-0.29%-0.19%-0.26%1 Month Performance1.23%9.18%8.36%5.82%1 Year Performance-29.23%10.11%55.89%22.47% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.0167 of 5 stars$2.47-3.9%$5.10+106.5%-34.0%$231.10M$32.31M-0.87230News CoverageBEAMBeam Therapeutics2.309 of 5 stars$16.64+1.2%$48.45+191.2%-38.9%$1.68B$60.27M-3.70510News CoveragePositive NewsCRSPCRISPR Therapeutics3.4608 of 5 stars$54.88+1.4%$71.60+30.5%+10.4%$4.99B$37.31M-10.11460Positive NewsAnalyst RevisionNTLAIntellia Therapeutics4.7318 of 5 stars$11.36-0.2%$29.05+155.7%-49.2%$1.22B$57.88M-2.42600News CoveragePositive NewsCRONCronos Group1.8455 of 5 stars$2.55-1.5%N/A+10.6%$976.75M$117.61M51.00450Analyst UpgradeGap DownHigh Trading VolumeORICOric Pharmaceuticals4.5739 of 5 stars$9.85+2.4%$17.63+78.9%+0.1%$956.66MN/A-5.2180News CoverageUPBUpstream Bio2.2424 of 5 stars$17.30+3.4%$56.50+226.6%N/A$932.64M$2.37M0.0038News CoveragePositive NewsPHARPharming Group2.7728 of 5 stars$13.55-5.1%$30.00+121.3%+81.6%$928.59M$297.20M-104.26280News CoverageShort Interest ↓Gap UpHigh Trading VolumeTRVITrevi Therapeutics2.5643 of 5 stars$7.42+1.9%$20.11+171.0%+130.1%$903.59MN/A-17.6720News CoveragePositive NewsURGNUrogen Pharma4.5928 of 5 stars$19.50+5.4%$32.00+64.1%+40.4%$902.07M$90.40M-5.87200Positive NewsPHATPhathom Pharmaceuticals2.8873 of 5 stars$12.58+8.7%$17.50+39.1%-28.3%$892.48M$114.04M-2.66110News Coverage Related Companies and Tools Related Companies Beam Therapeutics Competitors CRISPR Therapeutics Competitors Intellia Therapeutics Competitors Cronos Group Competitors Oric Pharmaceuticals Competitors Upstream Bio Competitors Pharming Group Competitors Trevi Therapeutics Competitors Urogen Pharma Competitors Phathom Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDIT) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
